ABSTRACT
Fifty-four (54) breast cancer patients, receiving tamoxifen, were enrolled into an evaluation of the status of the endometrium. Liquid-based cytology and immuno-cytochemical analysis were used for assessment. Our method proved viable in selective screening for differential diagnosis of endometrial pathology and cancer detection.
Subject(s)
Antineoplastic Agents, Hormonal/adverse effects , Biomarkers, Tumor/analysis , Breast Neoplasms/drug therapy , Endometrium/drug effects , Histocytological Preparation Techniques/methods , Tamoxifen/adverse effects , Uterine Neoplasms/diagnosis , Adult , Aged , Antineoplastic Agents, Hormonal/administration & dosage , Cytodiagnosis/methods , Diagnosis, Differential , Endometrium/pathology , Female , Humans , Immunohistochemistry , Ki-67 Antigen/analysis , Middle Aged , PTEN Phosphohydrolase/analysis , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis , Tamoxifen/administration & dosage , Uterine Neoplasms/chemically induced , Uterine Neoplasms/pathologySubject(s)
Genital Neoplasms, Female/epidemiology , Genital Neoplasms, Female/therapy , Female , Humans , Ovarian Neoplasms/epidemiology , Ovarian Neoplasms/therapy , Russia/epidemiology , Treatment Outcome , Uterine Cervical Neoplasms/epidemiology , Uterine Cervical Neoplasms/therapy , Uterine Neoplasms/epidemiology , Uterine Neoplasms/therapyABSTRACT
The investigation was concerned with clinical application of cardioxane (dexrazoxan, ICRF-187) which is intended to counteract the cardiotoxic effect of anthracycline drugs. It was tested in 24 courses of combination chemotherapy (CAP) in 48 cases of extended ovarian tumor. The "threshold" total dose of doxorubin (500 mg/m2) which caused persistent cardiomyopathy in such patients as well as cases of relapse was practically never reached due to the absence of therapeutic effect. The total dose of doxorubicin of 120 mg/m2 raised the likelihood of acute cardiac intoxication. With prophylactic administration of cardioxane, clinical signs of acute cardiointoxication were slight; irreversible intoxication was recorded in 0.8%. The drug improved tolerance; it neither increased the overall toxicity of combination chemotherapy nor affected the results.
Subject(s)
Antibiotics, Antineoplastic/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cardiovascular Agents/therapeutic use , Doxorubicin/adverse effects , Heart/drug effects , Ovarian Neoplasms/drug therapy , Razoxane/therapeutic use , Antibiotics, Antineoplastic/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Doxorubicin/therapeutic use , Female , Humans , Treatment OutcomeABSTRACT
A new non-steroid antiphlogistic medicine--tantum rosae--was tested in the course of treatment of 12 patients with gynecological malignancies. No postoperative complications in the area of the vaginal stump were reported. Good tolerance, primary adhesion of the stump and shorter admission period were recorded.
